Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Bridgebio Pharma Inc Market Cap
Based on ratings from 8 stock analysts, the Bridgebio Pharma Inc stock price is expected to increase by 44.35% in 12 months. This is calculated by using the average 12-month stock price forecast for Bridgebio Pharma Inc. The lowest target is $35.00 and the highest is $60.00. Please note analyst price targets are not guaranteed and could be missed completely.
About 8 Wall Street analysts have assignedBBIO 7 buy ratings, 1 hold ratings, and 0 sell ratings. This means that analysts expect Bridgebio Pharma Inc to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on BBIO. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| salim syed Mizuho Securities | Buy | $60.0 | maintained | Feb 12, 2024 |
| ram selvaraju H.C. Wainwright | Buy | $47.0 | reiterated | Feb 8, 2024 |
| greg harrison Bank of America Securities | Buy | $52.0 | maintained | Feb 7, 2024 |
| mani foroohar Leerink Partners | Buy | $57.0 | reiterated | Feb 7, 2024 |
| david lebovitz Citi | Buy | $42.0 | rated | Feb 5, 2024 |
| kostas biliouris BMO Capital | Hold | $37.0 | initiatedcoverage | Jan 31, 2024 |
| tiago fauth Wells Fargo | Buy | $58.0 | maintained | Jan 8, 2024 |
| salveen richter Goldman Sachs | Buy | None | maintained | Jan 8, 2024 |
| anupam rama J.P. Morgan | Buy | $35.0 | maintained | Nov 24, 2023 |
| thomas shrader BTIG | Hold | None | rated | Nov 17, 2023 |
| paul choi Goldman Sachs | Buy | $50.0 | reiterated | Nov 12, 2023 |
| tyler van buren TD Cowen | Buy | None | maintained | Nov 2, 2023 |
| joshua schimmer Cantor Fitzgerald | Buy | $50.0 | initiatedcoverage | Oct 23, 2023 |
| eun yang Jefferies | Hold | $33.0 | maintained | Aug 28, 2023 |
| dane leone Raymond James | Buy | $46.0 | maintained | Jul 18, 2023 |
| geoff meacham Bank of America Securities | Buy | $18.0 | reiterated | Mar 6, 2023 |
| eliana merle UBS | Buy | $30.0 | maintained | Jan 5, 2022 |
| george farmer Scotiabank | Buy | $44.0 | maintained | Aug 12, 2020 |
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
When did it IPO
2019
Staff Count
392
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Neil Kumar Ph.D.
Market Cap
$6.25B
In 2023, BBIO generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that BBIO's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
EXEL-USD
$20.72
FRSH-USD
$20.33
$85.63
LFUS-USD
$247.13
IONS-USD
$44.35
BPOP-USD
$83.48
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
